Procalcitonin as a Marker of Serious Bacterial Infections in Febrile Children Younger Than 3 Years Old
dc.contributor.author | Mahajan, Prashant | en_US |
dc.contributor.author | Grzybowski, Mary | en_US |
dc.contributor.author | Chen, Xinguang | en_US |
dc.contributor.author | Kannikeswaran, Nirupama | en_US |
dc.contributor.author | Stanley, Rachel | en_US |
dc.contributor.author | Singal, Bonita | en_US |
dc.contributor.author | Hoyle, John | en_US |
dc.contributor.author | Borgialli, Dominic | en_US |
dc.contributor.author | Duffy, Elizabeth | en_US |
dc.contributor.author | Kuppermann, Nathan | en_US |
dc.date.accessioned | 2014-03-05T18:19:07Z | |
dc.date.available | 2015-04-01T19:59:07Z | en_US |
dc.date.issued | 2014-02 | en_US |
dc.identifier.citation | Mahajan, Prashant; Grzybowski, Mary; Chen, Xinguang; Kannikeswaran, Nirupama; Stanley, Rachel; Singal, Bonita; Hoyle, John; Borgialli, Dominic; Duffy, Elizabeth; Kuppermann, Nathan (2014). "Procalcitonin as a Marker of Serious Bacterial Infections in Febrile Children Younger Than 3 Years Old." Academic Emergency Medicine (2): 171-179. | en_US |
dc.identifier.issn | 1069-6563 | en_US |
dc.identifier.issn | 1553-2712 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/106122 | |
dc.description.abstract | Objectives There is no perfectly sensitive or specific test for identifying young, febrile infants and children with occult serious bacterial infections ( SBI s). Studies of procalcitonin ( PCT ), a 116‐amino‐acid precursor of the hormone calcitonin, have demonstrated its potential as an acute‐phase biomarker for SBI . The objective of this study was to compare performance of serum PCT with traditional screening tests for detecting SBI s in young febrile infants and children. Methods This was a prospective, multicenter study on a convenience sample from May 2004 to December 2005. The study was conducted in four emergency departments ( ED s): one pediatric ED and three ED s with pediatric units, all with academic faculty on staff. A total of 226 febrile children 36 months old or younger who presented to the four participating ED s and were evaluated for SBI by blood, urine, and/or cerebral spinal fluid ( CSF ) cultures were included. Results The test characteristics (with 95% confidence intervals [CIs]) of the white blood cell (WBC) counts including neutrophil and band counts were compared with PCT for identifying SBI. Thirty children had SBIs (13.3%, 95% CI = 8.85 to 17.70). Four (13.3%) had bacteremia (including one with meningitis), 18 (60.0%) had urinary tract infections (UTIs), and eight (26.6%) had pneumonia. Children with SBIs had higher WBC counts (18.6 × 10 9 ± 8.6 × 10 9 cells/L vs. 11.5 × 10 9 ± 5.3 × 10 9 cells/L, p < 0.001), higher absolute neutrophil counts (ANCs; 10.6 × 10 9 ± 6.7 × 10 9 cells/L vs. 5.6 × 10 9 ± 3.8 × 10 9 cells/L, p = 0.009), higher absolute band counts (0.90 × 10 9 ± 1.1 × 10 9 cells/L vs. 0.35 × 10 9 ± 0.6 × 10 9 cells/L, p = 0.009), and higher PCT levels (2.9 ± 5.6 ng/ mL vs. 0.4 ± 0.8 ng/ mL , p = 0.021) than those without SBIs. In a multivariable logistic regression analysis, the absolute band count and PCT were the two screening tests independently associated with SBI, although the area under the receiver operating characteristic (ROC) curve for PCT was the largest (0.80, 95% CI = 0.71 to 0.89). Conclusions Procalcitonin is a more accurate biomarker than traditional screening tests for identifying young febrile infants and children with serious SBI s. Further study on a larger cohort of young febrile children is required to definitively determine the benefit of PCT over traditional laboratory screening tests for SBI s. Resumen Objetivos No existe un test con la sensibilidad o especificidad ideal es para identificar las infecciones bacterianas graves ( IBG ) ocultas en los niños durante su primera infancia con fiebre. Los estudios de procalcitonina ( PCT ), un precursor de 116‐aminoácidos de la hormona calcitonina, han demostrado su potencial como biomarcador de fase aguda para las IBG . El objetivo de este estudio es comparar el rendimiento de la PCT en plasma con las pruebas de despistaje tradicionales para la detección de IBG en los niños durante la primera infancia con fiebre. Metodología Estudio prospectivo multicéntrico en una muestra de conveniencia realizado de mayo de 2004 a diciembre realizado de 2005. Este estudio se llevó a cabo en cuatro servicios de urgencias ( SU ): un SU pediátrico y tres SU con unidades pediátricas, todos ellos con docentes universitarios en la plantilla. Se incluyeron 226 niños de 0 a 36 meses de edad con fiebre que acudieron a los cuatro SU participantes y se les evaluó para IBG mediante cultivos de sangre, orina y/o líquido cefalorraquídeo. Resultados Los resultados (con los intervalos de confianza [IC] al 95%) del número de leucocitos, incluyendo número neutrófilos y blastos, y de la PCT se compararon para identificar las IBG. Treinta niños tuvieron IBG (13,3%, IC 95% = 8,85 a 17,70). Cuatro (13,3%) tuvieron bacteremia (incluyendo uno con meningitis), 18 (60,0%) infección del tracto urinario y 8 (26,6%) neumonía. Los niños con IBG tuvieron mayor número de leucocitos (18.600 ± 8.600 cel/mm 3 vs. 11.500 ± 5.300 cel/mm 3 , p< 0,001), número absoluto de neutrófilos (NAN) (10.600 ± 6.700 cel/mm 3 vs. 5.600 ± 3.800 cel/mm 3 , p = 0,009), número absoluto de blastos (900 ± 1.100 cel/mm 3 vs. 350 ± 600 cel/mm 3 , p = 0,009) y valores de PCT (2,9 ng/ mL ± 5,6 ng/ mL vs. 0,4 ng/ mL ± 0,8 ng/ mL , p = 0,021), que aquéllos sin IBG. En un análisis multivariable de regresión logística, el número absoluto de blastos y la PCT fueron los dos test de despistaje que se asociaron de forma independiente con IBG, aunque el área bajo la curva de rendimiento diagnóstico para la PCT fue la mayor de los test de despistaje (0,80, IC 95% = 0,71 a 0,89). Conclusiones La PCT es un biomarcador más preciso que las pruebas de despistaje tradicionales para identificar a los niños durante la primera infancia con IBG . Se requieren futuros estudios en una mayor cohorte de niños durante la primera infancia con fiebre para determinar de forma definitiva el beneficio de la PCT sobre las pruebas de despistaje de laboratorio tradicionales para identificar las IBG . | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | Brahms Diagnostica | en_US |
dc.title | Procalcitonin as a Marker of Serious Bacterial Infections in Febrile Children Younger Than 3 Years Old | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/106122/1/acem12316.pdf | |
dc.identifier.doi | 10.1111/acem.12316 | en_US |
dc.identifier.source | Academic Emergency Medicine | en_US |
dc.identifier.citedreference | McCarthy PL, Sharpe MR, Spiesel SZ, et al. Observation scales to identify serious illness in febrile children. Pediatrics 1982; 70: 802 – 9. | en_US |
dc.identifier.citedreference | Galetto‐Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C‐reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 2003; 112: 1054 – 60. | en_US |
dc.identifier.citedreference | Lacour AG, Gervaix A, Zamora SA, et al. Procalcitonin, IL‐6, IL‐8, IL‐1 receptor antagonist and C‐reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr 2001; 160: 95 – 100. | en_US |
dc.identifier.citedreference | Yo CH, Hsieh PS, Lee SH, et al. Comparison of the test characteristics of procalcitonin to C‐reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta‐analysis. Ann Emerg Med 2012; 60: 591 – 600. | en_US |
dc.identifier.citedreference | Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515 – 8. | en_US |
dc.identifier.citedreference | Meisner M. Procalcitonin. A New Innovative Marker for Severe Infection and Sepsis: Biochemical and Clinical Aspects. Berlin, Germany: Brahms Diagnostica 1996, pp 14 – 21. | en_US |
dc.identifier.citedreference | Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 2004; 113: 1728 – 34. | en_US |
dc.identifier.citedreference | Hoberman A, Wald ER. Urinary tract infections in young febrile children. Pediatr Infect Dis J 1997; 16: 11 – 7. | en_US |
dc.identifier.citedreference | Irwig L, Bossuyt P, Glasziou P, Gatsonis C, Lijmer J. Evidence base of clinical diagnosis: Designing studies to ensure that estimates of test accuracy are transferable. BMJ 2002; 324: 669 – 71. | en_US |
dc.identifier.citedreference | Fleiss JL. Statistical Methods for Rates and Proportions, 2nd ed. New York, NY: John Wiley and Sons Ltd., 1981. | en_US |
dc.identifier.citedreference | Baraff LJ. Management of infants and young children with fever without source. Pediatr Ann 2008; 37: 673 – 9. | en_US |
dc.identifier.citedreference | Wenz B, Gennis P, Canova C, Burns ER. The clinical utility of the leukocyte differential in emergency medicine. Am J Clin Pathol 1986; 86: 298 – 303. | en_US |
dc.identifier.citedreference | Ardron MJ, Westengard JC, Dutcher TF. Band neutrophil counts are unnecessary for the diagnosis of infection in patients with normal total leukocyte counts. Am J Clin Pathol 1994; 102: 646 – 9. | en_US |
dc.identifier.citedreference | Kuppermann N, Walton EA. Immature neutrophils in the blood smears of young febrile children. Arch Pediatr Adolesc Med 1999; 153: 261 – 6. | en_US |
dc.identifier.citedreference | Luxmore B, Powell KR, Díaz SR, Novak RW. Absolute band counts in febrile infants: know your laboratory. Pediatrics 2002; 110 ( 1 Pt 1 ): e12. | en_US |
dc.identifier.citedreference | Bonsu BK, Chb M, Harper MB. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen? Ann Emerg Med 2003; 42: 216 – 25. | en_US |
dc.identifier.citedreference | Thayyil S, Shenoy M, Hamaluba M, Gupta A, Frater J, Verber IG. Is procalcitonin useful in early diagnosis of serious bacterial infections in children? Acta Paediatr 2005; 94: 155 – 8. | en_US |
dc.identifier.citedreference | Andreola B, Bressan S, Callegaro S, Liverani A, Plebani M, Da Dalt L. Procalcitonin and C‐reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J 2007; 26: 672 – 7. | en_US |
dc.identifier.citedreference | Herd D. In children under age three does procalcitonin help exclude serious bacterial infection in fever without focus? Arch Dis Child 2007; 92: 362 – 4. | en_US |
dc.identifier.citedreference | Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta‐analysis. Ann Emerg Med 2007; 5: 34 – 41. | en_US |
dc.identifier.citedreference | Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994‐1995: near disappearance of a vaccine‐preventable childhood disease. Emerg Infect Dis 1998; 4: 229 – 37. | en_US |
dc.identifier.citedreference | Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in the Northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23: 485 – 9. | en_US |
dc.identifier.citedreference | Olaciregui I, Hernández U, Muñoz JA, Emparanza JI, Landa JJ. Markers that predict serious bacterial infection in infants under 3 months of age presenting with fever of unknown origin. Arch Dis Child 2009; 94: 501 – 5. | en_US |
dc.identifier.citedreference | Maniaci V, Dauber A, Weiss S, Nylen E, Becker KL, Bachur R. Procalcitonin in young febrile infants for the detection of serious bacterial infections. Pediatrics 2008; 122: 701 – 10. | en_US |
dc.identifier.citedreference | Harper MB. Update on the management of the febrile infant. Clin Pediatr Emerg Med 2004; 5: 5 – 12. | en_US |
dc.identifier.citedreference | Chancey RJ, Jhaveri R. Fever without localizing signs in children: a review in the post‐Hib and postpneumococcal era. Minerva Pediatr 2009; 61: 489 – 501. | en_US |
dc.identifier.citedreference | DeAngelis C, Joffe A, Wilson M, Willis E. Iatrogenic risks and financial costs of hospitalizing febrile infants. Am J Dis Child 1983; 137: 1146 – 9. | en_US |
dc.identifier.citedreference | Hsiao AL, Baker MD. Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children. Curr Opin Pediatr 2005; 17: 56 – 61. | en_US |
dc.identifier.citedreference | Carrol ED, Newland P, Riordan FA, Thomson AP, Curtis N, Hart CA. Procalcitonin as a diagnostic marker of meningococcal disease in children presenting with fever and a rash. Arch Dis Child 2002; 86: 282 – 5. | en_US |
dc.identifier.citedreference | Fernández Lopez A, Luaces Cubells C, García García JJ, Fernández Pou J; Spanish Society of Pediatric Emergencies. Procalcitonin in pediatric emergency departments for early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and the utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003; 22: 895 – 903. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.